Introduction {#s1}
============

Epilepsy is one of the most common neurological disorders in humans with a prevalence of ∼1% and a lifetime incidence of up to 3% [@pgen.1000962-Hauser1]. The epilepsies present with a broad range of clinical features, and over 50 distinct epilepsy syndromes are now recognized. Particularly in a pediatric setting, a broad range of different epilepsy syndromes can be distinguished. Seizure disorders can roughly be divided into idiopathic or symptomatic epilepsies. While symptomatic epilepsies are due to an identifiable cause such as metabolic disorders, brain trauma or intracranial tumors, idiopathic seizure disorders occur in the absence of identifiable causal factors and are thought to have a strong genetic contribution.

Although it has long been observed that the idiopathic epilepsies have a genetic component, the genetic etiology of only a small fraction of cases can be determined. The role of copy number variants (CNVs) in intellectual disability (ID) [@pgen.1000962-deVries1]--[@pgen.1000962-ShawSmith1], autism [@pgen.1000962-Christian1]--[@pgen.1000962-Weiss1] and schizophrenia [@pgen.1000962-International1]--[@pgen.1000962-Xu1] has been extensively investigated. It has become increasingly clear that, collectively, rare variants contribute significantly to the etiology of these common diseases--following the rare variant common disease hypothesis. We hypothesize this can be extended to other neurological disorders and that rare CNVs significantly contribute to the genetic etiology of epilepsy.

Recently, in a study targeted to six genomic regions, recurrent microdeletions on chromosome 15q13.3, 16p13.11 and 15q11.2 were identified as important genetic factors predisposing to idiopathic generalized epilepsy (IGE) [@pgen.1000962-deKovel1]--[@pgen.1000962-Helbig1]. Here, we carry out whole-genome array comparative genomic hybridization (CGH) in a cohort of 517 individuals with mixed types of idiopathic epilepsy in order to discover novel copy number changes associated with epilepsy. We find recurrent microdeletions of 15q13.3, 16p13.11 and 15q11.2 each in ∼1% of affected individuals, confirming previous studies [@pgen.1000962-deKovel1]--[@pgen.1000962-Helbig1]. In addition to recurrent rearrangements at rearrangement-prone regions, we show that, overall, 8.9% of affected individuals have one or more rare copy number changes involving at least one gene.

Results {#s2}
=======

We performed genome-wide array CGH to detect copy number changes in 517 patients with mixed types of epilepsy. Of these, 399 have idiopathic generalized epilepsy (IGE), 50 have benign epilepsy with centrotemporal spikes (BECTS) and 68 have other types of idiopathic seizure disorders ([Table 1](#pgen-1000962-t001){ref-type="table"}). We used a custom microarray with high-density targeted coverage of 107 regions of the genome flanked by large, highly homologous duplications, termed rearrangement hotspots [@pgen.1000962-Bailey1]. In addition, probes were evenly spaced throughout the remainder of the genome with average probe spacing of ∼38 kb. Overall, we find that 46 probands (8.9%) carry one or more rare CNVs not previously reported in the 2493 unrelated controls [@pgen.1000962-Itsara1]. The rare CNVs detected in our cohort range in size from 13 kb to 15.9 Mb (average 1.2 Mb; median 600 kb), and the majority (69%) are deletion events.

10.1371/journal.pgen.1000962.t001

###### Phenotypes of probands evaluated by array CGH.

![](pgen.1000962.t001){#pgen-1000962-t001-1}

  Type of epilepsy                             N            Hotspot CNVs detected                Other CNVs detected           Total
  ---------------------------------------- --------- ----------------------------------- ------------------------------------ --------
  **IGE (n = 399)**                                                                                                           
  Juvenile myoclonic epilepsy (JME)           189     8[∧](#nt103){ref-type="table-fn"}   9[∧](#nt103){ref-type="table-fn"}      17
  Absence epilepsy (AE)                       94                      5                   5[\*](#nt102){ref-type="table-fn"}     10
  IGE with GTCS only                          33                      0                                   2                      2
  IGE unclassified                            63                      2                                   4                      6
  Benign myoclonic epilepsy of infancy         5                      0                                   0                      0
  Myoclonic astatic epilepsy (MAE)            15                      0                                   2                      2
  **Idiopathic focal epilepsy (n = 63)**                                                                                      
  BECTS                                       50                      3                                   2                      5
  ABPE                                        13                      0                                   0                      0
  **Other (n = 55)**                                                                                                          
  ESES                                         4                      0                                   0                      0
  Landau-Kleffner syndrome                     3                      0                                   0                      0
  Severe IGE of infancy (SIGEI)               15                      1                                   1                      2
  West syndrome                                4                      0                   2[\*](#nt102){ref-type="table-fn"}     2
  IC/NC                                       10                      1                   2[\*](#nt102){ref-type="table-fn"}     3
  Unclassified                                19                      0                                   2                      2
  **Total**                                 **517**                **20**                               **31**                 **51**

IGE, idiopathic generalized epilepsy; GTCS, generalized tonic-clonic seizures; BECTS, benign epilepsy with centrotemporal spikes; ABPE, atypical benign partial epilepsy; ESES, electrical status epilepticus during slow-wave sleep; IC, infantile convulsions; NC, neonatal convulsions;

\*indicates two events in a single individual;

**∧:** two individuals (EMJ071 and EMJ117) each carrying one hotspot and one non-hotspot event.

Rearrangements at genomic hotspots {#s2a}
----------------------------------

We first evaluated rearrangement hotspots for copy number changes. We found 20 probands (3.9%) with copy number changes at known rearrangement hotspots including 15q13.3 deletions (n = 5), 16p13.11 deletions (n = 5), 15q11.2 BP1--BP2 deletions (n = 5), 1q21.1 deletions (n = 2), a 16p12.1 deletion (n = 1), a 16p11.2 duplication (n = 1) and a more distal 16p11.2 deletion (n = 1) ([Table 2](#pgen-1000962-t002){ref-type="table"}, [Figure 1](#pgen-1000962-g001){ref-type="fig"}). We also identified four individuals with duplications of 15q11.2 BP1--BP2; because duplications of this region are frequent in the general population, we classified these duplications as polymorphic events. These results confirm our previous studies and emphasize the importance of deletions of 15q13.3, 16p13.11 and 15q11.2 BP1--BP2 as frequent genetic susceptibility factors in epilepsy [@pgen.1000962-deKovel1]--[@pgen.1000962-Helbig1]. All three regions have also been associated with ID, autism and/or schizophrenia [@pgen.1000962-International1], [@pgen.1000962-Stefansson1], [@pgen.1000962-BenShachar1]--[@pgen.1000962-Ullmann1], as have deletions at 1q21.1 [@pgen.1000962-BrunettiPierri1], [@pgen.1000962-Mefford2], two distinct regions of 16p11.2 [@pgen.1000962-Kumar1], [@pgen.1000962-Weiss1], [@pgen.1000962-Bijlsma1]--[@pgen.1000962-McCarthy1] and 16p12 [@pgen.1000962-Girirajan1], which were also detected in our cohort. Deletions of 16p13.11 (5/517 vs 0/2493 controls, p = 0.00014, Fisher\'s exact test), 15q13.3 (5/517 vs 0/2493, p = 0.00014) and 15q11.2 (5/517 vs. 4/2493, p = 0.010) are significantly enriched in our epilepsy cohort and together account for 2.9% of cases.

![Deletions and duplications at genomic rearrangement hotspots in 20 probands.\
Array CGH results are depicted for (A) 15q13.3, chr15: 28.0--31.0 Mb, (B) 16p13.11, chr16: 14.5--18.5 Mb, (C) 15q11.2, chr15: 20.0--20.9 Mb, (D) 1q21.1, chr1: 144.0--147.5 Mb, (E) 16p12.1, chr16: 21.6--22.6 Mb, (F) 16p11.2, chr16:28.6--29.1 Mb, and (G) 16p11.2, chr16: 29.0--30.3 Mb. For each individual, deviations of probe log~2~ ratios from 0 are depicted by gray and black lines. Those exceeding a threshold of 1.5 s.d. from the mean probe ratio are colored green and red to represent relative gains and losses, respectively. Segmental duplications of increasing similarity (90--98%, 98--99%, and \>99%) are represented by gray, yellow, and orange bars, respectively. RefSeq genes are depicted in blue.](pgen.1000962.g001){#pgen-1000962-g001}

10.1371/journal.pgen.1000962.t002

###### Rare copy number variants in 517 patients with epilepsy.

![](pgen.1000962.t002){#pgen-1000962-t002-2}

  Case                                              Chromosome Location   HS   Coordinates (build36; Mb)     Size     CNV                 Inheritance                  Phenotype     *RefSeq* genes (n)   Possible candidate genes
  ------------------------------------------------ --------------------- ---- --------------------------- ---------- ----- ----------------------------------------- -------------- -------------------- --------------------------
  **Idopathic Generalized Epilepsies (n = 399)**                                                                                                                                                         
  EMJ 049                                                 1q21.1          Y       Chr1: 145.0--145.9        900 kb    Del                     \-                          JME                8                     *GJA8*
  ND02006                                                 15q11.2         Y        Chr15: 20.2--20.8        600 kb    Del                     \-                          IAE                4                    *CYFIP1*
  ND03383                                                 15q11.2         Y        Chr15: 20.2--20.8        600 kb    Del                     \-                          CAE                4                    *CYFIP1*
  ND06631                                                 15q11.2         Y        Chr15: 20.2--20.8        600 kb    Del                   Inh (P)                       CAE                4                    *CYFIP1*
  K004                                                    15q11.2         Y        Chr15: 20.2--20.8        600 kb    Del                   Inh (P)                       IGE                4                    *CYFIP1*
  EPI 62                                                  15q13.3         Y        Chr15: 28.7--30.1        1.4 Mb    Del                     \-                          IAE                6                    *CHRNA7*
  EMJ 001[\*\*](#nt107){ref-type="table-fn"}              15q13.3         Y        Chr15: 28.7--30.1        1.4 Mb    Del                     \-                          JME                6                    *CHRNA7*
  EMJ 002                                                 15q13.3         Y        Chr15: 28.7--30.1        1.4 Mb    Del                     \-                          JME                6                    *CHRNA7*
  EMJ 020[\*\*](#nt107){ref-type="table-fn"}              15q13.3         Y        Chr15: 28.7--30.1        1.4 Mb    Del                     \-                          JME                6                    *CHRNA7*
  IA G5                                                   15q13.3         Y        Chr15: 28.7--30.1        1.4 Mb    Del                     \-                        IGE + ID             6                    *CHRNA7*
  EMJ 162                                                 16p11.2         Y        Chr16: 29.5--30.2        700 kb    Dup                     \-                          JME                30                   *SEZ6L2*
  ND3074                                                 16p13.11         Y        Chr16:15.4--16.3         900 kb    Del                   Inh (M)                       CAE                6                     *NDE1*
  EPI 17                                                 16p13.11         Y        Chr16:15.4--16.3         900 kb    Del                     \-                          JME                6                     *NDE1*
  EMJ 071[\*](#nt106){ref-type="table-fn"}               16p13.11         Y        Chr16:15.4--16.3         900 kb    Del                     \-                          JME                6                     *NDE1*
  EMJ 117[\*](#nt106){ref-type="table-fn"}               16p13.11         Y        Chr16: 15.4--18.5        3.1 Mb    Del                     \-                          JME                7                     *NDE1*
  ND05586                                                 1p31.1                  Chr1: 72.04--72.15       111.3 kb   Del                   Inh (P)                       CAE                1                    *NEGR1*
  ND05260[\*](#nt106){ref-type="table-fn"}                4q22.2                  Chr4: 94.18--94.83       646.6 kb   Del                   Inh (M)                       CAE                1                    *GRID2*
  K 111                                                   5p15.33                  Chr5: 0.72--1.43        713.0 kb   Dup   Inh (M[∧](#nt105){ref-type="table-fn"})       MAE                10                *NKD2, SLCA18*
  EP007.1                                                 5q33.2                  Chr5: 153.2--160.3        7.1 Mb    Del                  Not in M                     IGE + ID             44                   *CYFIP2*
  EMJ 005                                                  6q12                   Chr6: 65.03--66.09       1.06 Mb    Dup                     \-                          JME                1                     *EYS*
  ND01440                                                 7q11.22                 Chr7: 69.38--69.46       78.7 kb    Del                     \-                          JME                1                    *AUTS2*
  K 039                                                   7q36.1                 Chr7: 151.35--151.43      85.8 kb    Del                   Inh (P)                       MAE                1                   *GALNT11*
  ND03578                                                8q21-q22                 Chr8: 83.97--97.20       15.9 Mb    Dup                   Inh (P)                      JME+ID              50                    *many*
  EMJ 013                                                 9p21.3                  Chr9: 21.21--21.63       427.5 kb   Del                     \-                          JME                9                    *KLHL9*
  EP005.1                                                 9q21.32                  Chr9: 83.9--85.2        1.30 Mb    Del                   Inh (M)                       IGE                2                    *RASEF*
  ND05260[\*](#nt106){ref-type="table-fn"}                9q31.3                 Chr9: 113.33--114.33      1.01 Mb    Dup                   Inh (M)                       CAE                10          
  EMJ 071[\*](#nt106){ref-type="table-fn"}                13q31.1                 Chr13: 84.69--85.36      671.8 kb   Del                     \-                          JME                1                   *SLITRK6*
  EMJ 067                                                 14q24.2                 Chr14: 70.96--71.23      268.6 kb   Del                     \-                          JME                1                   *SIPA1L1*
  EPI 66                                                  15q25.2                 Chr15: 83.00--83.12      117.4 kb   Dup                     \-                          IAE                3                     *NBM*
  ND03244                                                 16q23.1                 Chr16: 74.49--75.27      785.8 kb   Dup                     \-                       GTCS only             1                   *CNTNAP4*
  EPI 52                                                  17p11.2                 Chr17: 19.92--19.94      13.3 kb    Del                     \-                       GTCS only             1                    *CYTSB*
  EMJ 117[\*](#nt106){ref-type="table-fn"}                17p11.2                 Chr17: 19.92--19.94      17.5 kb    Del                     \-                          JME                1                    *CYTSB*
  EPI 40                                                   17q12                  Chr17: 30.53--30.87      338.5 kb   Del                     \-                          IAE                7                    *UNC45*
  EMJ 039                                                 18q11.2                 Chr18: 19.66--20.50      840.4 kb   Dup                     \-                          JME                6           
  EMJ 069                                                 18q11.2                 Chr18: 19.66--20.50      840.4 kb   Dup                     \-                          JME                6           
  ND02416                                                 21q21.1                 Chr21: 16.21--18.81      2.59 Mb    Dup                   Inh (M)                     IGE + ID             7           
  EPI 26                                                  Xp22.31                  ChrX: 7.78--8.39        605.5 kb   Dup                     \-                          IGE                4                    *PNPLA4*
  **Idiopathic Focal Epilepsies (n = 63)**                                                                                                                                                               
  EPI 60                                                  1q21.1          Y       Chr1: 145.0--145.9        900 kb    Del                     \-                         BECTS               8           
  K 105                                                   16p12.1         Y        Chr16: 21.8--22.3        500 kb    Del                     \-                         BECTS               7           
  EPI 21                                                 16p13.11         Y        Chr16: 15.4--16.3        900 kb    Del                     \-                         BECTS               6                     *NDE1*
  EPI 58                                                  4q35.1                 Chr4: 186.30--186.61      302.4 kb   Dup                     \-                         BECTS               8                *SLC25A, SNX25*
  K 093                                                   8p23.1                  Chr8: 10.19--10.37       173.1 kb   Del                     \-                         BECTS               1                     *MSRA*
  **Other (n = 55)**                                                                                                                                                                                     
  K 047                                                   15q11.2         Y        Chr15: 20.2--20.8        600 kb    Del   brother[∧](#nt105){ref-type="table-fn"}        IC                4                    *CYFIP1*
  K 027                                                   16p11.2         Y        Chr16:28.7--28.9         200 kb    Del                     \-                         SIGEI               9           
  K 109                                                    2q35                  Chr2: 218.36--218.94      571.9 kb   Dup                     \-                         SIGEI               11          
  EPI 51[\*](#nt106){ref-type="table-fn"}                 5q35.1                 Chr5: 167.62--167.89      268.7 kb   Dup                     \-                          West               4                     *WWC1*
  EPI 51[\*](#nt106){ref-type="table-fn"}                 5q35.1                 Chr5: 169.43--169.64      230.0 kb   Dup                     \-                          West               4                 *DOCK2, FOXI1*
  K 054                                                   7q11.22                 Chr7: 69.38--69.42       38.3 kb    Del                     \-                      Unclassified           1                    *AUTS2*
  K034[\*](#nt106){ref-type="table-fn"}                    7q35                   Chr7:146.06--146.36      304.4 kb   Del   Inh (P[∧](#nt105){ref-type="table-fn"})        NC                1                   *CNTNAP2*
  ND08273                                               15q13.3-q14               Chr15: 30.66--32.44      1.78 Mb    Dup                   Inh (M)                   Unclassified           15          
  K034[\*](#nt106){ref-type="table-fn"}                   17p13.1                 Chr17:10.36--10.72        370 kb    Del   Inh (P[∧](#nt105){ref-type="table-fn"})        NC                7                 *MYH1-3; SCO*

HS, hotspot region; Del, deletion; Dup, duplication; Inh, inherited; M, maternal; P, paternal;

**∧:** affected; -, parents unavailable; JME, juvenile myoclonic epilepsy; IAE, idiopathic absence epilepsy; CAE childhood absence epilepsy; IGE, idiopathic generalized epilepsy; GTCS, generalized tonic clonic seizures only; ID, intellectual disability; BECTS, benign epilepsy with centrotemporal spikes; IC, infantile convulsions; SIGEI, several idiopathic generalized epilepsy of infancy; NC, neonatal convulsions;

\*two CNVs detected in same individual;

\*\*15q13 deletions previously detected by MLPA [@pgen.1000962-Helbig2].

Rare or unique deletions involving potential candidate genes {#s2b}
------------------------------------------------------------

We next focused on non-hotspot CNVs that overlap one or more genes and are not present in the control cohort of 2493 individuals [@pgen.1000962-Itsara1]. We identified 28 individuals with at least one rare gene-containing deletion or duplication, and five individuals each carry two rare CNVs ([Table 2](#pgen-1000962-t002){ref-type="table"}). Fifteen of the events we detected involve a single gene. Two genes were altered in two patients each: *AUTS2* deletions were identified in one proband with juvenile myoclonic epilepsy (JME) and one proband with unclassified non-lesional epilepsy with features of atypical benign partial epilepsy (ABPE) [@pgen.1000962-Doose1]. Deletions involving *CTYSB* (*SPECC1*) were identified in two probands with IGE. All other single-gene CNVs were seen only once. Seventeen events involved multiple genes, one of which was observed in two different individuals with JME (duplication of 18q11, [Table 2](#pgen-1000962-t002){ref-type="table"}).

Individuals with multiple rare CNVs {#s2c}
-----------------------------------

We found five individuals with two rare CNVs ([Figure 2](#pgen-1000962-g002){ref-type="fig"}). Two patients with JME and a deletion of 16p13.11 (EMJ071 and EMJ117) each have a second rare deletion. EMJ071 has a large deletion on chromosome 13 that removes the *SLITRK6* gene, a member of the SLITRK gene family involved in controlling neurite outgrowth; individual EMJ117 also has a deletion involving the *CTYSB* gene. Case ND05260 (childhood absence epilepsy, CAE) carries a 647-kb deletion within the *GRID2* gene, which encodes a glutamate receptor expressed in the cerebellum, and a 1-Mb duplication of 9q31. Though both are maternally inherited, neither has been reported in controls. Case EPI 51 (idiopathic West syndrome) has two apparently independent duplications of chromosome 5q35, each containing several genes. Finally, we identified one proband with neonatal convulsions (NC) carrying a deletion within the *CNTNAP2* gene that spans exons 2--4 as well as a 370-kb deletion of 17p13 involving 7 genes.

![Two rare CNVs in five probands.\
Array CGH results are shown for the for two rare CNVs detected in probands EMJ071 (A), ND05260 (B), EPI51 (C), K034 (D), and EMJ117 (E). Array CGH results are depicted as in [Figure 1](#pgen-1000962-g001){ref-type="fig"}; segmental duplications are not shown in this figure.](pgen.1000962.g002){#pgen-1000962-g002}

DNA from one of more family members was available for analysis in 14 cases. Inheritance, if determined, is shown in [Table 2](#pgen-1000962-t002){ref-type="table"}. In twelve cases, we determined that one or both CNVs in the proband were inherited; in three cases the transmitting parent is also affected. In one case (EP007.1), the CNV was not found in the mother, but the father was unavailable. In another case (K047), parents were unavailable, but a brother was found to carry the same CNV suggesting one of the parents carries the same CNV.

Discussion {#s3}
==========

In this study, we performed whole-genome array CGH in a series of 517 individuals with a presenting diagnosis of idiopathic epilepsy in order to discover novel copy number changes associated with epilepsy. While our previous studies were targeted to specific genomic regions in probands with IGE [@pgen.1000962-Dibbens1], [@pgen.1000962-Helbig1], here we present data from whole-genome analysis on probands with IGE and extend our analysis to other idiopathic epilepsy syndromes. In total, we identified 46 individuals (8.9%) with 51 rearrangements that may be pathogenic as they were not found in controls or were significantly enriched in our epilepsy cohort.

Hotspot rearrangements {#s3a}
----------------------

Rearrangements at several genomic hotspots have been associated with a range of neurocognitive disorders. In our cohort of 517 probands with epilepsy, we find deletions at 15q13.3, 16p13.11 and 15q11.2 in 2.9% of our cases. Interestingly, all of the deletions of 15q13.3 (n = 5) and 4/5 deletions at 16p13.11 and 15q11.2 were in probands with IGE, accounting for 3.3% of the patients with IGE in our cohort confirming our previous findings. While it is possible that deletions of 15q13.3 are also predisposing to non-IGE epilepsy syndromes, we did not find this to be the case in our series (n = 118). Additional large cohorts of patients with focal epilepsy or epileptic encephalopathy will be required to determine whether these deletions also play a significant role in other subtypes of epilepsy.

Deletions of 16p13.11 have previously been associated with intellectual disability +/− congenital anomalies in one study [@pgen.1000962-Hannes1]. Three of four probands with 16p13.11 deletions in that series had epilepsy; two further fetal cases had brain abnormalities. The findings in this cohort and one previous study of IGE [@pgen.1000962-deKovel1] suggest that deletions of 16p13.11 are more frequent in epilepsy (0.5--1% of cases) than in other phenotypes including ID and autism [@pgen.1000962-Hannes1], [@pgen.1000962-Mefford1], [@pgen.1000962-Ullmann1], and may be as frequent as 15q13.3 deletions in individuals with IGE. Deletions and duplications of this region have also been reported in schizophrenia, though the associations have not been statistically significant [@pgen.1000962-Kirov1], [@pgen.1000962-Need1].

Deletions of 15q13.3, detected in five individuals with IGE in our series, have been associated with a wide range of phenotypes including ID, autism, epilepsy and schizophrenia [@pgen.1000962-International1], [@pgen.1000962-Stefansson1], [@pgen.1000962-deKovel1]--[@pgen.1000962-Helbig1], [@pgen.1000962-BenShachar1], [@pgen.1000962-Miller1], [@pgen.1000962-Pagnamenta1], [@pgen.1000962-Sharp2], [@pgen.1000962-vanBon1]. The gene within the 15q13.3 region that is most likely responsible for the epilepsy phenotype is *CHRNA7*, a subunit of the nicotinic acetylcholine receptor. At least two small studies have failed to identify causal point mutations in the *CHRNA7* gene in autosomal dominant nocturnal frontal lobe epilepsy [@pgen.1000962-Bonati1] and JME [@pgen.1000962-Taske1], but additional studies should be performed to further evaluate affected individuals for mutations. A recent publication identifying atypical rearrangements with exclusive deletions of *CHRNA7* further emphasizes the importance of *CHRNA7* as the main candidate gene in this region [@pgen.1000962-Shinawi1].

Compared to the above structural genomic variants, copy number variation at 15q11.2 between breakpoints BP1 and BP2 of the Prader-Willi and Angelman syndrome region is more common in the general population with the BP1--BP2 deletion present in 0.2% of unaffected individuals. Despite this, deletions between BP1 and BP2 have now been reported as enriched in patients with schizophrenia [@pgen.1000962-Kirov1], [@pgen.1000962-Stefansson1], ID [@pgen.1000962-Mefford1] and epilepsy [@pgen.1000962-deKovel1]. Furthermore, there is evidence that patients with Prader-Willi or Angelman syndrome who have deletions including BP1--BP2 are more severely affected [@pgen.1000962-Butler1]--[@pgen.1000962-Sahoo1]. In this study, we also find enrichment of deletions at this locus in affected individuals. Together, these studies suggest that deletion of the 15q11.2 BP1--BP2 region confers susceptibility to a wide range of neuropsychiatric conditions, albeit with incomplete penetrance.

Two patients in our series, one each with JME and BECTS, have deletions of 1q21.1, which have been previously associated with a wide range of phenotypes, including intellectually disability and developmental delay [@pgen.1000962-BrunettiPierri1], [@pgen.1000962-Mefford2], schizophrenia [@pgen.1000962-International1], [@pgen.1000962-Stefansson1], [@pgen.1000962-Walsh1], congenital heart disease [@pgen.1000962-Christiansen1], [@pgen.1000962-Greenway1] and cataracts [@pgen.1000962-Mefford2], [@pgen.1000962-Redon1]. In two large studies of patients who present primarily with cognitive or developmental delay, 5/42 (11.9%) patients also had seizures [@pgen.1000962-BrunettiPierri1], [@pgen.1000962-Mefford2]; 1 of 10 patients with schizophrenia and a 1q21.1 deletion also had epilepsy [@pgen.1000962-International1]. Identifying 1q21.1 microdeletions in patients with idiopathic generalized and idiopathic focal epilepsies suggests that variation at this locus predisposes to a broad range of seizure disorders crossing traditional diagnostic boundaries.

In addition, we identified one patient (EMJ162) with JME and a duplication of 16p11.2 (chr16: 29.5--30.2 Mb), which has been associated with autism, developmental delay and schizophrenia [@pgen.1000962-Kumar1]--[@pgen.1000962-Sebat1], [@pgen.1000962-Weiss1], [@pgen.1000962-Mefford1], [@pgen.1000962-Bijlsma1], [@pgen.1000962-McCarthy1]. Finally, we identified one individual with severe idiopathic generalized epilepsy of infancy (SIGEI) (K027) with a more distal deletion of 16p11.2 (chr16: 27.7--28.9 Mb), recently associated with severe early-onset obesity and ID [@pgen.1000962-Bochukova1], and one patient with BECTS (K105) and a deletion of 16p12.1 (chr16: 20.2--20.8 Mb), also associated with ID and other neurodevelopmental defects [@pgen.1000962-Girirajan1]. Thus, our data adds to the phenotypic spectrum associated with rearrangements at several genomic hotspot regions. In particular, we identify hotspot deletions in two patients with BECTS. Gene identification in BECTS, despite representing the most common focal epilepsy syndrome of childhood, has been elusive so far. Here, we suggest that some recurrent hotspot deletions might predispose to both idiopathic generalized and focal epilepsies.

Non-hotspot rearrangements {#s3b}
--------------------------

We detected 18 deletions and 16 duplications that are not associated with rearrangement hotspots. Fifteen events involve a single gene; of these, 12 are deletions. Although all of the CNVs reported here are not found in our control set of 2493 individuals, it is possible that some are rare but benign CNVs. However, many of the CNVs we identified contain one of more plausible candidate genes for epilepsy ([Table 2](#pgen-1000962-t002){ref-type="table"}).

We identified a deletion of exons 2--4 in the *CNTNAP2* gene in a proband with neonatal seizures. *CNTNAP2* has been identified as a candidate gene for autism [@pgen.1000962-Alarcon1]--[@pgen.1000962-Bakkaloglu1], and heterozygous deletions involving the gene were reported in three patients with schizophrenia and autism [@pgen.1000962-Friedman2]. The deletion is predicted to cause an in-frame deletion of 153 amino acids in the resulting protein. The same patient has a 370-kb deletion of 17p13 that deletes seven genes and has not been seen in our control cohort. We also identified a patient with a duplication encompassing a related gene, *CNTNAP4*. Finally, two individuals in our cohort have overlapping deletions within *AUTS2*. This gene is disrupted by *de novo* balanced translocations in three unrelated individuals with mental retardation [@pgen.1000962-Kalscheuer1] and a pair of twins with autism and mental retardation [@pgen.1000962-Sultana1], suggesting a role for *AUTS2* in normal cognitive development. The two deletions we detected are intragenic and overlapping.

CNVs in epilepsy subtypes {#s3c}
-------------------------

Previous studies of CNVs in epilepsy have focused on probands with IGE. It is known from studies of families with autosomal dominant epilepsy that a wide range of seizure types can be caused by the same single-gene mutation. For example, Dravet syndrome, a severe early-onset disorder associated with poor cognitive outcome, and the milder generalized epilepsy with febrile seizures plus (GEFS+) syndrome are both caused by mutations in the *SCN1A* gene [@pgen.1000962-Claes1]--[@pgen.1000962-Fujiwara1]. Therefore, we included probands with common idiopathic focal epilepsies and non-lesional, idiopathic epilepsies. Some of our probands were diagnosed with specific epilepsy syndromes, including myoclonic astatic epilepsy (Doose Syndrome), atypical benign partial epilepsy [@pgen.1000962-Doose1], Landau-Kleffner syndrome, idiopathic West syndrome, severe idiopathic generalized epilepsy of infancy [@pgen.1000962-Doose2] and benign neonatal or infantile seizures. These particular epilepsy syndromes are usually associated with normal MRI results. We find that 6.6% of probands with IGE and 7.9% of those with idiopathic focal epilepsy harbor rare CNVs that may underlie their epilepsy phenotype. Notably, 12.7% of patients with other, often more severe forms of epilepsy in our series carry one or more rare CNVs. In our series, the vast majority of patients with deletions of 15q13.3, 16p13.11 and 15q11.2 BP1--BP2 were in the IGE cohort, accounting for 3.3% of cases. In the non-IGE patients, a deletion of 15q11.2 was found in a single patient with infantile seizures and a deletion of 16p13.11 was found in one patient with BECTS, suggesting that deletions at these three genomic hotspots confer greater risk for IGE than other types of epilepsy.

In summary, we find that 46/517 probands (8.9%) with various forms of idiopathic epilepsy carry one or more rare CNVs that may predispose to seizures, a frequency similar to that in studies of patients who present with other neurocognitive phenotypes, including ID, autism and schizophrenia. Furthermore, we identified CNVs involving genes and genomic regions previously identified in patients with the neurocognitive phenotypes listed above, suggesting common genetic etiological factors for these disorders. Our data suggest that rare CNVs are important in many subtypes of idiopathic epilepsies, including idiopathic generalized and idiopathic focal epilepsies as well as specific idiopathic, non-lesional epilepsy syndromes. The genomic regions and genes identified in this study are potential novel candidate genes for epilepsy.

Materials and Methods {#s4}
=====================

Ethics statement {#s4a}
----------------

Patients were collected at five centers after appropriate human subjects approval and informed consent at each site.

Patient cohorts {#s4b}
---------------

Patients were collected at five centers: (1) 140 probands with a primary diagnosis of JME, CAE, absence epilepsy, IGE or idiopathic epilepsy were selected from the NINDS repository (<http://ccr.coriell.org/ninds>); (2) 160 patients are probands with a primary diagnosis of JME from Switzerland. Patients from cohorts (1) and (2) were previously analyzed using MLPA for the *CHRNA7* gene [@pgen.1000962-Helbig2], and two probands (EMJ001 and EMJ020) were determined to have 15q13.3 microdeletions by that method; they were not previously analyzed for any other copy number changes. (3) 186 German patients came from two cohorts: 76 patients from a population-based cohort from Northern Germany (POPGEN cohort) and 110 patients with childhood-onset epilepsy collected at the University of Kiel. Finally, 41 patients with various idiopathic generalized epilepsies collected at (4) the University of Iowa and (5) at Washington University, St. Louis. DNA from the NINDS repository was derived from cell lines; DNA from all other cohorts was directly from blood. Patients were diagnosed according to the widely used 1989 ILAE classification [@pgen.1000962-ILAE1]. In addition, several pediatric patients were diagnosed with specific syndromes not yet recognized in the ILAE classification ([Table 1](#pgen-1000962-t001){ref-type="table"}). Patients with non-lesional, idiopathic epilepsies in which diagnostic criteria of the recent ILAE classification for particular epilepsy syndromes were not met were labeled as "unclassified".

Array comparative genomic hybridization (CGH) {#s4c}
---------------------------------------------

Array CGH was performed using either custom or commercially available oligonucleotide arrays containing 135,000 isothermal probes (Roche NimbleGen, Inc.). Customized arrays (459 samples) were designed with higher density probe coverage in known rearrangement hotspot regions (average probe spacing 2.5 kb) with lower density whole-genome backbone coverage (average probe spacing 38 kb). A subset of samples (n = 62) was analyzed using a commercially available whole-genome array (Roche NimbleGen 12×135 k whole-genome tiling array) with average probe spacing throughout the genome of 21 kb.

Data analysis {#s4d}
-------------

Data were analyzed according to manufacturer\'s instructions using NimbleScan software to generate normalized log~2~ fluorescence intensity ratios. Then, for each sample, normalized log intensity ratios are transformed into z-scores using the chromosome-specific mean and standard deviation. Z-scores are subsequently used to classify probes as "increased", "normal" and "decreased" copy-number using a three-state Hidden Markov Model (HMM). The HMM was implemented using HMMSeg [@pgen.1000962-Day1], which assumes Gaussian emission probabilities. The "increased" and "decreased" states are defined to have the same standard deviation as the "normal" state but with mean z-score two standard deviations above and below the mean, respectively. Probe-by-probe HMM state assignments are merged into segments according to the following criteria: consecutive probes of the same state less than 50 kb apart are merged, and if two segments of the same state are separated by an intervening sequence of ≤5 probes and ≤10 kb, both segments and intervening sequence are called as a single variant. CNV calls are filtered to eliminate (i) events containing \<5 probes, (ii) CNVs with \>50% overlap in a series of 2493 control individuals [@pgen.1000962-Itsara1] and (iii) events that had no overlap with RefSeq genes. In addition, when comparing CNV calls to control CNVs, we eliminated calls for which there was insufficient probe coverage (\<5 probes) in the control data to identify the same or similar CNV. Filtered copy number changes are also visually inspected in a genome browser.

This study used samples from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (<http://ccr.coriell.org/ninds>), as well as clinical data. NINDS Repository sample numbers corresponding to the samples used are available upon request.
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